髋关节疼痛治疗解决方案市场（按治疗类型、年龄层、最终用户和分销管道划分），全球预测（2026-2032年）

2025 年髋关节疼痛治疗解决方案市值为 4.2731 亿美元，预计到 2026 年将成长至 4.4528 亿美元，复合年增长率为 5.21%，到 2032 年将达到 6.0994 亿美元。

关键市场统计数据
基准年 2025	4.2731亿美元
预计年份：2026年	4.4528亿美元
预测年份 2032	6.0994亿美元
复合年增长率 (%)	5.21%

本文全面介绍了现代医学中髋关节疼痛治疗方案的临床复杂性、相关人员趋势和策略重点。

髋关节疼痛反映了临床复杂性、患者期望和不断发展的治疗方法三者交汇融合的特征。近年来，治疗途径已从保守治疗扩展到先进的外科手术和再生医学干预，而支付方和医疗服务提供者也在修订准入、报销和临床通讯协定，以平衡疗效和成本。人口结构变化、活动模式改变和技术进步之间的相互作用，凸显了整合观点的重要性，该视角应涵盖治疗方法类型、医疗机构和通路。

本文详细说明了正在重塑髋关节疼痛治疗方案和护理服务的主要临床、技术和报销主导所带来的变革。

临床创新、不断变化的医疗保健模式以及患者期望的转变，共同重塑了髋关节疼痛的评估和治疗方式。影像技术和诊断演算法的进步，使得关节和软组织病变的识别更加早期、精准，从而支持早期疗育策略和个人化治疗方案的选择。同时，微创手术技术和关节镜技术的改进，也改变了手术全期流程，使部分患者能够缩短住院时间，并加快功能恢復。

检验2025年价格调整对美国髋关节疼痛治疗相关人员的供应链韧性、筹资策略和临床经济学的影响。

近期政策週期中实施的关税调整对医疗设备和药品供应链产生了显着的连锁反应，影响了膝关节疼痛治疗的采购、定价和临床规划。外科植入、器械和某些生物製剂处理试剂盒的组件通常来自全球供应商。进口关税的提高将推高到岸成本，并可能迫使供应商重新评估其筹资策略。事实上，这种压力已促使一些供应链管理者延长合约期限、拓展供应商范围，或尽可能转向国内采购，以稳定采购并保障利润。

全面的細項分析揭示了治疗方法类型、医疗保健环境、通路和年龄层如何共同塑造临床需求和采纳路径。

治疗方法方案的选择取决于临床症状和患者目标。保守治疗优先考虑辅助器具、结构化物理治疗和体重管理，以延缓侵入性手术并改善功能。药物治疗着重于针对性症状管理，包括使用皮质类固醇治疗局部炎症，使用非类固醇抗发炎药物缓解全身疼痛，以及在严格遵循通讯协定的前提下，谨慎使用鸦片类药物治疗急性重度疼痛。再生医学疗法（例如富血小板血浆疗法和干细胞疗法）是一个新兴领域，患者和临床医生都在寻求生物学解决方案来促进癒合。手术方案根据其侵入性和适应症进行划分，髋关节镜手术适用于局部关节内问题，微创技术可减轻术后恢復负担，而全髋置换术则用于治疗进行性退化性疾病或大规模的结构性损伤。

分析区域差异，重点介绍美洲、欧洲、中东和非洲以及亚太地区在报销制度、医疗服务基础设施和采用模式方面的差异。

在美洲，医疗报销模式多元，私部门正积极采用创新技术。整形外科诊所和门诊手术中心之间密切合作，微创手术和快速復健计画备受重视。支付方谈判的趋势影响着医疗设备的选择和综合报销方案的设计，而遍远地区的医疗资源匮乏和专科医生分布的区域差异则影响着转诊模式，因此需要利用远端医疗手段，开展有针对性的推广和后续随访，以弥合医疗保健方面的差距。

实用的企业资料，检验证据生成、供应灵活性和综合临床支援如何推动解决方案供应商之间的竞争情报。

领先的製造商和服务供应商透过临床证据、整合式服务交付和灵活的商业模式来脱颖而出。那些优先考虑强有力的临床计画（包括投资于比较疗效研究、真实世界结果追踪和系统性的上市后监测）的公司，往往能获得医疗机构更高的采纳率和支付方的认可。当证据显示微创和再生医学解决方案能够改善功能性结果并带来特定手术益处时，与临床领导者和专家中心建立合作关係能够加速这些解决方案的早期应用。

为产业领导者提供策略建议，以整合证据产生、供应链韧性和商业化策略，从而实现持续应用和影响力。

优先考虑符合支付方价值标准和对患者及医疗系统至关重要的临床终点的证据。投资前瞻性註册研究和真实世界证据，以量化功能改善、再入院率降低和总医疗成本。同时，开发灵活的合约模式，以反映全面的诊疗路径并提供可预测的定价，从而便于支付方评估。加强临床、市场进入和商业团队之间的跨职能协作，以加速与支付方的对话并支援将医疗服务整合到诊疗路径中。

一项解释透明的研究设计，结合了多种调查方法（文献综述、相关人员访谈和比较路径检验），以确保研究结果的可靠性。

本分析系统地回顾了同行评审的临床文献、监管指南和已发布的政策文件，以绘製髋关节疼痛的治疗路径和临床结果图谱。除了文献综述外，还对临床医生、医院采购人员和配送专业人员进行定性相关人员调查，检验仅凭文献无法揭示的实际挑战和营运限制。这些相关人员访谈有助于对不同医疗机构的实际实践模式和实施障碍进行三角验证。

简洁扼要的结论重点阐述了成功实施髋关节疼痛治疗并实现其价值交付的策略重点和营运槓桿。

髋关节疼痛的治疗越来越取决于临床创新、以价值主导的报销机制和营运执行之间的相互作用。随着保守治疗、药物治疗、再生疗法和手术治疗方案的逐步成熟，关键的差异化因素将在于相关人员如何将临床证据转化为可及且经济有效的治疗途径。能够将严谨的疗效数据与切实可行的服务模式和供应链韧性相结合的医疗服务提供者和製造商，将在医疗系统和支付方中赢得优先地位。

目录

第一章：序言

第二章调查方法

• 研究设计
• 研究框架
• 市场规模预测
• 数据三角测量
• 调查结果
• 调查前提
• 调查限制

第三章执行摘要

• 首席主管观点
• 市场规模和成长趋势
• 2025年市占率分析
• FPNV定位矩阵，2025
• 新的商机
• 下一代经营模式
• 产业蓝图

第四章 市场概览

• 产业生态系与价值链分析
• 波特五力分析
• PESTEL 分析
• 市场展望
• 上市策略

第五章 市场洞察

• 消费者洞察与终端用户观点
• 消费者体验基准
• 机会地图
• 分销通路分析
• 价格趋势分析
• 监理合规和标准框架
• ESG与永续性分析
• 中断和风险情景
• 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 按治疗方法的髋关节疼痛治疗解决方案市场

• 保守治疗
  • 辅助器具
  • 物理治疗
  • 体重管理
• 药物治疗
  • 皮质类固醇
  • 非类固醇消炎剂（NSAIDs）
  • 阿片类药物
• 再生医学
  • 富血小板血浆
  • 干细胞疗法
• 外科
  • 髋关节镜检查
  • 微创
  • 全髋关节置换术

9. 依年龄层分類的髋关节疼痛治疗方案市场

• 成人版
• 老年人
• 儿童

第十章 按最终使用者分類的髋关节疼痛治疗解决方案市场

• 门诊治疗中心
• 居家医疗
• 医院
• 整形外科诊所

第十一章 按分销管道分類的髋关节疼痛治疗解决方案市场

• 在线的
• 离线

12. 按地区分類的髋关节疼痛治疗解决方案市场

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十三章 按群体分類的髋关节疼痛治疗解决方案市场

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

14. 各国髋关节疼痛治疗计画市场

• 我们
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

15. 美国髋关节疼痛治疗计画市场

第十六章：中国髋关节疼痛治疗方案市场

第十七章 竞争格局

• 市场集中度分析，2025年
  • 浓度比（CR）
  • 赫芬达尔-赫希曼指数 (HHI)
• 近期趋势及影响分析，2025 年
• 2025年产品系列分析
• 基准分析，2025 年
• Alkem Laboratories Ltd.
• Anika Therapeutics, Inc.
• B. Braun Melsungen AG
• Bioventus Inc.
• Cipla Ltd.
• DJO Global, Inc.
• Fix Health（YourPhysio Pvt. Ltd.）
• Healyos Pvt. Ltd.
• Jiva Ayurveda Clinic Pvt. Ltd.
• Johnson & Johnson
• Medtronic plc
• Meril Life Sciences Pvt. Ltd.
• Ortho Sport & Spine Physicians, LLC
• Penn Medicine
• Pfizer Inc.
• RegenOrthoSport Pvt. Ltd.
• Smith & Nephew plc
• Stryker Corporation
• Teva Pharmaceutical Industries Ltd.
• Zimmer Biomet Holdings, Inc.

The Hip Pain Therapy Solutions Market was valued at USD 427.31 million in 2025 and is projected to grow to USD 445.28 million in 2026, with a CAGR of 5.21%, reaching USD 609.94 million by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 427.31 million
Estimated Year [2026]	USD 445.28 million
Forecast Year [2032]	USD 609.94 million
CAGR (%)	5.21%

Comprehensive introduction outlining the clinical complexity, stakeholder dynamics, and strategic priorities framing hip pain therapy solutions in contemporary care

Hip pain represents a convergence of clinical complexity, patient expectations, and evolving therapeutic modalities. In recent years, care pathways have diversified from conservative management through to advanced surgical and regenerative interventions, while payers and providers have recalibrated access, reimbursement, and clinical protocols to balance outcomes and costs. The interplay of demographic shifts, activity patterns, and technological advances has elevated the importance of an integrated view that spans therapy type, care setting, and distribution channel.

This executive summary synthesizes key patterns shaping the sector, spotlighting clinical innovation, supply chain dynamics, payer influences, and regional contrasts. It frames actionable principles for industry leaders, clinical program managers, and policy planners who must translate emerging evidence into operational plans. The narrative emphasizes practical implications rather than granular estimates, providing a foundation to prioritize investments, refine stakeholder engagement, and accelerate adoption of clinically validated approaches.

By focusing on the mechanisms driving demand, adoption, and competitive differentiation, readers will gain a compact, strategically oriented perspective. The content that follows bridges clinical realities with market-facing levers, enabling readers to identify immediate risks and near-term opportunities while preparing for longer-term shifts in therapy delivery and patient expectations.

Detailed exposition of the major clinical, technological, and reimbursement-driven transformations reshaping hip pain therapy selection and care delivery

Clinical innovation, shifting reimbursement models, and evolving patient expectations have collectively redefined how hip pain is evaluated and treated. Advances in imaging and diagnostic algorithms enable earlier, more precise identification of joint and soft tissue pathology, which in turn supports earlier intervention strategies and tailored therapy selection. At the same time, minimally invasive surgical techniques and refinements in arthroscopy have altered perioperative pathways, reducing length of stay and accelerating functional recovery for selected patients.

Concurrently, nonoperative options are expanding beyond traditional analgesia and physical therapy to include targeted regenerative interventions and integrated care models that emphasize multidisciplinary rehabilitation and long-term function. Health systems and orthopedic providers increasingly align care bundles with value metrics, tying pathway adherence to outcome-based reimbursement and patient-reported measures. As a result, commercial and clinical stakeholders must adapt product positioning, evidence generation, and value communication to meet tighter scrutiny from payers and institutions.

Technology and data are accelerating these trends. Digital therapeutics, remote monitoring, and tele-rehabilitation increasingly complement in-person care, enabling longitudinal management and better adherence tracking. As these forces interact, the market is shifting toward evidence-driven, patient-centric models that privilege demonstrable functional improvement and cost-effective care delivery.

Examination of how 2025 tariff adjustments reshaped supply resilience, procurement strategies, and clinical economics for hip pain therapy stakeholders in the United States

Tariff adjustments enacted in recent policy cycles have created material ripple effects across medical device and pharmaceutical supply chains, which in turn influence procurement, pricing, and clinical planning for hip pain therapies. Components used in surgical implants, instruments, and certain biologic processing kits often originate from global suppliers; increased import duties can raise landed costs and compel providers to reassess sourcing strategies. In practice, this pressure has led some supply managers to shift toward longer contract terms, diversify vendor lists, or source domestically where feasible to stabilize procurement and protect margin.

Beyond direct cost implications, tariffs can prompt manufacturers to revisit supply chain footprints and operational footprints, accelerating moves to localize critical manufacturing steps or nearshore selected operations to mitigate future policy volatility. These strategic responses have secondary effects on capital expenditure and product lead times, sometimes lengthening the interval between order and delivery and complicating inventory planning in hospitals and ambulatory centers.

Clinicians and health system leaders respond to these dynamics by enhancing cross-functional planning between clinical, procurement, and finance teams. In turn, commercial organizations that offer flexible contract structures, localized inventory support, or bundled service offerings find it easier to maintain adoption momentum. Ultimately, tariffs represent a macro-level risk that reshuffles cost bases and supply relationships, incentivizing resilience, transparency, and tighter coordination across the ecosystem.

Comprehensive segmentation insights revealing how therapy modalities, care settings, distribution channels, and age cohorts collectively shape clinical demand and adoption pathways

Therapy selection reflects clinical presentation and patient goals, with conservative approaches prioritizing assistive devices, structured physical therapy, and weight management to delay invasive interventions and improve function. Pharmacologic strategies emphasize targeted symptom control via corticosteroids for localized inflammation, NSAIDs for broad analgesic needs, and cautious opioid use reserved for acute, severe pain under strict protocols. Regenerative options, including platelet-rich plasma and stem cell therapies, occupy a growing niche where patients and clinicians seek biologically oriented solutions to augment healing. Surgical pathways subdivide by invasiveness and indication, with hip arthroscopy applied to focal intra-articular problems, minimally invasive techniques reducing recovery burdens, and total hip replacement reserved for advanced degenerative disease and large-scale structural compromise.

Care delivery settings shape access, throughput, and the patient experience. Ambulatory care centers-whether hospital-affiliated or standalone-offer focused procedural throughput and shorter stays, while home care models, spanning professional home nursing to self-managed rehabilitation, extend recovery into the patient's environment and can reduce readmission risk. Hospitals, including general institutions, specialty orthopedic centers, and teaching hospitals, provide the full spectrum of acute and complex care, and orthopedic clinics, whether group or private practices, often serve as the primary referral and follow-up hub.

The distribution landscape influences availability and channel economics. Hospital pharmacies, split between inpatient and outpatient services, manage immediate perioperative and discharge medication needs. Online pharmacies, through direct-to-patient offerings or third-party platforms, expand convenience for chronic pharmacologic regimens. Retail pharmacies, both chain and independent, remain essential for community access and adherence. Age stratification also matters: adults aged 18-64 experience different activity-related etiologies than geriatric cohorts aged 65 and above, who present with degenerative patterns and distinct comorbidity profiles, while pediatric patients require tailored diagnostic and therapeutic approaches reflecting growth and development considerations.

Nuanced regional analysis highlighting how reimbursement, provider infrastructure, and adoption patterns vary across the Americas, Europe Middle East and Africa, and Asia Pacific

The Americas display heterogeneous reimbursement models and robust private-sector innovation adoption, with strong integration between orthopedics practices and ambulatory procedural centers that favor minimally invasive surgery and rapid recovery programs. Payer negotiation dynamics influence device selection and bundle design, while regional disparities in rural access and specialist distribution shape referral patterns, prompting targeted outreach and telehealth-enabled follow-up models to bridge care gaps.

Europe, the Middle East & Africa exhibits a complex mosaic of public and private financing, with many health systems emphasizing cost-effectiveness and standardized care pathways. Regulatory scrutiny and centralized procurement mechanisms often lead to longer adoption cycles for novel devices and biologics, yet there is persistent interest in interventions that demonstrably reduce hospital stay and long-term disability. Variability across jurisdictions necessitates localized evidence generation and payer dialogue to secure pathway inclusion.

Asia-Pacific combines rapid capacity expansion, increasing surgical throughput, and a rising emphasis on regenerative medicine and biologics. Many markets are modernizing infrastructure, accelerating adoption of outpatient surgery models and leveraging private investment to enhance orthopedic service lines. However, heterogeneity in reimbursement and private-public mix requires tailored commercialization strategies that account for local clinical practices, price sensitivity, and distribution logistics.

Actionable corporate intelligence examining how evidence generation, supply agility, and integrated clinical support drive competitive leadership among solution providers

Leading manufacturers and service providers differentiate through clinical evidence, integrated service offerings, and flexible commercial models. Those that prioritize robust clinical programs-investing in comparative effectiveness studies, real-world outcome tracking, and structured post-market surveillance-tend to secure stronger institutional adoption and payer recognition. Partnerships with clinician leaders and specialty centers accelerate early adoption of minimally invasive and regenerative solutions when evidence demonstrates improved functional outcomes and procedure-specific benefits.

Competitive advantage also emerges from supply chain agility and service models that reduce friction for health systems. Companies that support bundled procurement, provide local inventory management, or offer clinical training and pathway integration services reduce adoption barriers. Additionally, those developing digital adjuncts-tele-rehabilitation platforms, remote monitoring solutions, and patient engagement tools-enhance long-term adherence and capture outcomes data that strengthen the value proposition.

Strategic mergers, targeted acquisitions, and alliances with distributors or specialized clinics further expand geographic reach and expedite entry into constrained reimbursement environments. Ultimately, firms that balance rigorous evidence programs with pragmatic commercial support and outcome-focused partnerships position themselves to lead in a market where institutional decision-making increasingly emphasizes total cost of care and demonstrable functional benefit.

Strategically focused recommendations to help industry leaders align evidence generation, supply resiliency, and commercialization tactics for sustained adoption and impact

Prioritize evidence that aligns with payer value criteria and clinical endpoints that matter to patients and systems; invest in prospective registries and real-world evidence that quantify functional improvement, reduced readmission, and total cost of care. Simultaneously, develop flexible contracting models that reflect bundled care pathways and offer predictable pricing that eases payer evaluation. Strengthen cross-functional engagement between clinical affairs, market access, and commercial teams to accelerate payer dialogues and support inclusion in care pathways.

Enhance supply chain resilience by diversifying supplier bases, nearshoring critical components where possible, and offering localized inventory support to mitigate tariff-driven and geopolitical risks. Build clinical training and pathway-integration programs that reduce friction for adoption and demonstrate measurable improvements in perioperative efficiency and patient satisfaction. Leverage digital adjuncts-remote monitoring, tele-rehabilitation, and patient engagement platforms-to extend care beyond the clinic and capture longitudinal outcomes that reinforce the therapy's value proposition.

Finally, adopt a region-specific approach to commercialization, tailoring evidence packages, pricing frameworks, and distribution partnerships to local reimbursement realities and provider infrastructures. By combining rigorous evidence generation with operational flexibility and a patient-centered narrative, industry leaders can achieve sustained adoption and meaningful clinical impact.

Transparent explanation of the mixed-methods research design combining literature synthesis, stakeholder interviews, and comparative pathway validation to ensure robust insights

This analysis integrates a structured review of peer-reviewed clinical literature, regulatory guidance, and publicly available policy documents to map therapeutic pathways and clinical outcomes relevant to hip pain. The approach pairs literature synthesis with qualitative stakeholder engagement across clinicians, hospital procurement leaders, and distribution specialists to validate practical implications and to surface operational constraints that literature alone may not reveal. These stakeholder interviews support triangulation of real-world practice patterns and adoption barriers across different care settings.

Comparative pathway analysis evaluates how clinical decision trees vary by presentation, comorbidity, and patient age, and considers how distribution and end-user dynamics shape access. The methodology also examines payer mechanisms and procurement frameworks to understand reimbursement hurdles and adoption timelines. Wherever possible, evidence is contextualized with case examples of care model redesigns and implementation lessons that inform recommendations.

Throughout, the research prioritizes transparency in data sources and analytical assumptions, ensuring that conclusions reflect convergent signals from multiple inputs rather than single-study inferences. This mixed-methods approach yields practical insights for clinical, commercial, and policy stakeholders seeking to align strategy with evolving care realities.

Concise conclusion distilling the strategic priorities and operational levers that will define successful hip pain therapy adoption and value delivery

Hip pain therapy is increasingly defined by the interplay of clinical innovation, value-driven reimbursement, and operational execution. As conservative, pharmacologic, regenerative, and surgical options mature in parallel, the decisive differentiator will be how stakeholders translate clinical evidence into accessible, cost-effective care pathways. Providers and manufacturers that align rigorous outcomes data with pragmatic service models and supply chain resilience will secure preferential positioning with health systems and payers.

Immediate priorities include strengthening evidence generation that speaks to functional outcomes and long-term recovery, optimizing channel and site-of-care strategies to match patient needs and payer expectations, and implementing procurement and partnership models that mitigate policy and tariff-related uncertainties. By focusing on these levers, organizations can both improve patient experiences and create defensible commercial advantages.

Looking ahead, the sector will continue to evolve around integrated care models and digital enhancements that support continuous monitoring and rehabilitation. Stakeholders who proactively invest in these areas will be best placed to capture value while improving clinical outcomes and operational efficiency across diverse care settings.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Hip Pain Therapy Solutions Market, by Therapy Type

• 8.1. Conservative
  • 8.1.1. Assistive Devices
  • 8.1.2. Physical Therapy
  • 8.1.3. Weight Management
• 8.2. Pharmacologic
  • 8.2.1. Corticosteroids
  • 8.2.2. NSAIDs
  • 8.2.3. Opioids
• 8.3. Regenerative
  • 8.3.1. Platelet-Rich Plasma
  • 8.3.2. Stem Cell Therapy
• 8.4. Surgical
  • 8.4.1. Hip Arthroscopy
  • 8.4.2. Minimally Invasive
  • 8.4.3. Total Hip Replacement

9. Hip Pain Therapy Solutions Market, by Age Group

• 9.1. Adult
• 9.2. Geriatric
• 9.3. Pediatric

10. Hip Pain Therapy Solutions Market, by End User

• 10.1. Ambulatory Care Centers
• 10.2. Home Care
• 10.3. Hospitals
• 10.4. Orthopedic Clinics

11. Hip Pain Therapy Solutions Market, by Distribution Channel

• 11.1. Online
• 11.2. Offline

12. Hip Pain Therapy Solutions Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. Hip Pain Therapy Solutions Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Hip Pain Therapy Solutions Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. United States Hip Pain Therapy Solutions Market

16. China Hip Pain Therapy Solutions Market

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025
• 17.5. Alkem Laboratories Ltd.
• 17.6. Anika Therapeutics, Inc.
• 17.7. B. Braun Melsungen AG
• 17.8. Bioventus Inc.
• 17.9. Cipla Ltd.
• 17.10. DJO Global, Inc.
• 17.11. Fix Health (YourPhysio Pvt. Ltd.)
• 17.12. Healyos Pvt. Ltd.
• 17.13. Jiva Ayurveda Clinic Pvt. Ltd.
• 17.14. Johnson & Johnson
• 17.15. Medtronic plc
• 17.16. Meril Life Sciences Pvt. Ltd.
• 17.17. Ortho Sport & Spine Physicians, LLC
• 17.18. Penn Medicine
• 17.19. Pfizer Inc.
• 17.20. RegenOrthoSport Pvt. Ltd.
• 17.21. Smith & Nephew plc
• 17.22. Stryker Corporation
• 17.23. Teva Pharmaceutical Industries Ltd.
• 17.24. Zimmer Biomet Holdings, Inc.

LIST OF FIGURES

• FIGURE 1. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SHARE, BY KEY PLAYER, 2025
• FIGURE 3. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET, FPNV POSITIONING MATRIX, 2025
• FIGURE 4. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 5. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 7. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 9. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 11. UNITED STATES HIP PAIN THERAPY SOLUTIONS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 12. CHINA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

• TABLE 1. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 2. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
• TABLE 3. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY CONSERVATIVE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 4. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY CONSERVATIVE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 5. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY CONSERVATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 6. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY CONSERVATIVE, 2018-2032 (USD MILLION)
• TABLE 7. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY ASSISTIVE DEVICES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 8. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY ASSISTIVE DEVICES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 9. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY ASSISTIVE DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 10. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 11. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PHYSICAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 12. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PHYSICAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 13. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY WEIGHT MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 14. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY WEIGHT MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 15. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY WEIGHT MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 16. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PHARMACOLOGIC, BY REGION, 2018-2032 (USD MILLION)
• TABLE 17. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PHARMACOLOGIC, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 18. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PHARMACOLOGIC, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 19. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PHARMACOLOGIC, 2018-2032 (USD MILLION)
• TABLE 20. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 21. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 22. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 23. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY NSAIDS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 24. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY NSAIDS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 25. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY NSAIDS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 26. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 27. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY OPIOIDS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 28. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 29. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY REGENERATIVE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 30. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY REGENERATIVE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 31. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY REGENERATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 32. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY REGENERATIVE, 2018-2032 (USD MILLION)
• TABLE 33. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, BY REGION, 2018-2032 (USD MILLION)
• TABLE 34. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 35. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 36. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 37. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 38. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 39. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY SURGICAL, BY REGION, 2018-2032 (USD MILLION)
• TABLE 40. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY SURGICAL, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 41. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY SURGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 42. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
• TABLE 43. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY HIP ARTHROSCOPY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 44. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY HIP ARTHROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 45. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY HIP ARTHROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 46. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY MINIMALLY INVASIVE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 47. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY MINIMALLY INVASIVE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 48. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY MINIMALLY INVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 49. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY TOTAL HIP REPLACEMENT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 50. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY TOTAL HIP REPLACEMENT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 51. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY TOTAL HIP REPLACEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 52. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 53. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 54. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 55. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 56. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
• TABLE 57. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 58. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 59. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
• TABLE 60. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 61. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 62. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 63. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 64. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 65. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 66. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 67. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 68. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 69. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 70. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 71. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 72. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY ORTHOPEDIC CLINICS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 73. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY ORTHOPEDIC CLINICS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 74. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY ORTHOPEDIC CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 75. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 76. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 77. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 78. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 79. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 80. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 81. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 82. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 83. AMERICAS HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 84. AMERICAS HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
• TABLE 85. AMERICAS HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY CONSERVATIVE, 2018-2032 (USD MILLION)
• TABLE 86. AMERICAS HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PHARMACOLOGIC, 2018-2032 (USD MILLION)
• TABLE 87. AMERICAS HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY REGENERATIVE, 2018-2032 (USD MILLION)
• TABLE 88. AMERICAS HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
• TABLE 89. AMERICAS HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 90. AMERICAS HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 91. AMERICAS HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 92. NORTH AMERICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 93. NORTH AMERICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
• TABLE 94. NORTH AMERICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY CONSERVATIVE, 2018-2032 (USD MILLION)
• TABLE 95. NORTH AMERICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PHARMACOLOGIC, 2018-2032 (USD MILLION)
• TABLE 96. NORTH AMERICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY REGENERATIVE, 2018-2032 (USD MILLION)
• TABLE 97. NORTH AMERICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
• TABLE 98. NORTH AMERICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 99. NORTH AMERICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 100. NORTH AMERICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 101. LATIN AMERICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 102. LATIN AMERICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
• TABLE 103. LATIN AMERICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY CONSERVATIVE, 2018-2032 (USD MILLION)
• TABLE 104. LATIN AMERICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PHARMACOLOGIC, 2018-2032 (USD MILLION)
• TABLE 105. LATIN AMERICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY REGENERATIVE, 2018-2032 (USD MILLION)
• TABLE 106. LATIN AMERICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
• TABLE 107. LATIN AMERICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 108. LATIN AMERICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 109. LATIN AMERICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 110. EUROPE, MIDDLE EAST & AFRICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 111. EUROPE, MIDDLE EAST & AFRICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
• TABLE 112. EUROPE, MIDDLE EAST & AFRICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY CONSERVATIVE, 2018-2032 (USD MILLION)
• TABLE 113. EUROPE, MIDDLE EAST & AFRICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PHARMACOLOGIC, 2018-2032 (USD MILLION)
• TABLE 114. EUROPE, MIDDLE EAST & AFRICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY REGENERATIVE, 2018-2032 (USD MILLION)
• TABLE 115. EUROPE, MIDDLE EAST & AFRICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
• TABLE 116. EUROPE, MIDDLE EAST & AFRICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 117. EUROPE, MIDDLE EAST & AFRICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 118. EUROPE, MIDDLE EAST & AFRICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 119. EUROPE HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 120. EUROPE HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
• TABLE 121. EUROPE HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY CONSERVATIVE, 2018-2032 (USD MILLION)
• TABLE 122. EUROPE HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PHARMACOLOGIC, 2018-2032 (USD MILLION)
• TABLE 123. EUROPE HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY REGENERATIVE, 2018-2032 (USD MILLION)
• TABLE 124. EUROPE HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
• TABLE 125. EUROPE HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 126. EUROPE HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 127. EUROPE HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 128. MIDDLE EAST HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 129. MIDDLE EAST HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
• TABLE 130. MIDDLE EAST HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY CONSERVATIVE, 2018-2032 (USD MILLION)
• TABLE 131. MIDDLE EAST HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PHARMACOLOGIC, 2018-2032 (USD MILLION)
• TABLE 132. MIDDLE EAST HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY REGENERATIVE, 2018-2032 (USD MILLION)
• TABLE 133. MIDDLE EAST HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
• TABLE 134. MIDDLE EAST HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 135. MIDDLE EAST HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 136. MIDDLE EAST HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 137. AFRICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 138. AFRICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
• TABLE 139. AFRICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY CONSERVATIVE, 2018-2032 (USD MILLION)
• TABLE 140. AFRICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PHARMACOLOGIC, 2018-2032 (USD MILLION)
• TABLE 141. AFRICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY REGENERATIVE, 2018-2032 (USD MILLION)
• TABLE 142. AFRICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
• TABLE 143. AFRICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 144. AFRICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 145. AFRICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 146. ASIA-PACIFIC HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 147. ASIA-PACIFIC HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
• TABLE 148. ASIA-PACIFIC HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY CONSERVATIVE, 2018-2032 (USD MILLION)
• TABLE 149. ASIA-PACIFIC HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PHARMACOLOGIC, 2018-2032 (USD MILLION)
• TABLE 150. ASIA-PACIFIC HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY REGENERATIVE, 2018-2032 (USD MILLION)
• TABLE 151. ASIA-PACIFIC HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
• TABLE 152. ASIA-PACIFIC HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 153. ASIA-PACIFIC HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 154. ASIA-PACIFIC HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 155. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 156. ASEAN HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 157. ASEAN HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
• TABLE 158. ASEAN HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY CONSERVATIVE, 2018-2032 (USD MILLION)
• TABLE 159. ASEAN HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PHARMACOLOGIC, 2018-2032 (USD MILLION)
• TABLE 160. ASEAN HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY REGENERATIVE, 2018-2032 (USD MILLION)
• TABLE 161. ASEAN HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
• TABLE 162. ASEAN HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 163. ASEAN HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 164. ASEAN HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 165. GCC HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 166. GCC HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
• TABLE 167. GCC HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY CONSERVATIVE, 2018-2032 (USD MILLION)
• TABLE 168. GCC HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PHARMACOLOGIC, 2018-2032 (USD MILLION)
• TABLE 169. GCC HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY REGENERATIVE, 2018-2032 (USD MILLION)
• TABLE 170. GCC HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
• TABLE 171. GCC HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 172. GCC HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 173. GCC HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 174. EUROPEAN UNION HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 175. EUROPEAN UNION HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
• TABLE 176. EUROPEAN UNION HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY CONSERVATIVE, 2018-2032 (USD MILLION)
• TABLE 177. EUROPEAN UNION HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PHARMACOLOGIC, 2018-2032 (USD MILLION)
• TABLE 178. EUROPEAN UNION HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY REGENERATIVE, 2018-2032 (USD MILLION)
• TABLE 179. EUROPEAN UNION HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
• TABLE 180. EUROPEAN UNION HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 181. EUROPEAN UNION HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 182. EUROPEAN UNION HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 183. BRICS HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 184. BRICS HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
• TABLE 185. BRICS HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY CONSERVATIVE, 2018-2032 (USD MILLION)
• TABLE 186. BRICS HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PHARMACOLOGIC, 2018-2032 (USD MILLION)
• TABLE 187. BRICS HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY REGENERATIVE, 2018-2032 (USD MILLION)
• TABLE 188. BRICS HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
• TABLE 189. BRICS HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 190. BRICS HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 191. BRICS HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 192. G7 HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 193. G7 HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
• TABLE 194. G7 HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY CONSERVATIVE, 2018-2032 (USD MILLION)
• TABLE 195. G7 HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PHARMACOLOGIC, 2018-2032 (USD MILLION)
• TABLE 196. G7 HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY REGENERATIVE, 2018-2032 (USD MILLION)
• TABLE 197. G7 HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
• TABLE 198. G7 HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 199. G7 HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 200. G7 HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 201. NATO HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 202. NATO HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
• TABLE 203. NATO HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY CONSERVATIVE, 2018-2032 (USD MILLION)
• TABLE 204. NATO HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PHARMACOLOGIC, 2018-2032 (USD MILLION)
• TABLE 205. NATO HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY REGENERATIVE, 2018-2032 (USD MILLION)
• TABLE 206. NATO HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
• TABLE 207. NATO HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 208. NATO HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 209. NATO HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 210. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 211. UNITED STATES HIP PAIN THERAPY SOLUTIONS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 212. UNITED STATES HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
• TABLE 213. UNITED STATES HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY CONSERVATIVE, 2018-2032 (USD MILLION)
• TABLE 214. UNITED STATES HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PHARMACOLOGIC, 2018-2032 (USD MILLION)
• TABLE 215. UNITED STATES HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY REGENERATIVE, 2018-2032 (USD MILLION)
• TABLE 216. UNITED STATES HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
• TABLE 217. UNITED STATES HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 218. UNITED STATES HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 219. UNITED STATES HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 220. CHINA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 221. CHINA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
• TABLE 222. CHINA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY CONSERVATIVE, 2018-2032 (USD MILLION)
• TABLE 223. CHINA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PHARMACOLOGIC, 2018-2032 (USD MILLION)
• TABLE 224. CHINA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY REGENERATIVE, 2018-2032 (USD MILLION)
• TABLE 225. CHINA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
• TABLE 226. CHINA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 227. CHINA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 228. CHINA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)